BIT Capital GmbH Has $2.48 Million Stake in argenx SE (NASDAQ:ARGX)

BIT Capital GmbH grew its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 22.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,032 shares of the company's stock after purchasing an additional 731 shares during the period. BIT Capital GmbH's holdings in argenx were worth $2,480,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Whipplewood Advisors LLC purchased a new position in argenx in the fourth quarter valued at about $37,000. Global Retirement Partners LLC lifted its position in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares during the period. Whittier Trust Co. of Nevada Inc. grew its position in shares of argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after purchasing an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

argenx stock traded down $8.39 during midday trading on Monday, reaching $580.77. The stock had a trading volume of 201,179 shares, compared to its average volume of 289,380. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The firm's fifty day simple moving average is $628.26 and its 200-day simple moving average is $602.12. The stock has a market capitalization of $35.29 billion, a P/E ratio of -659.70 and a beta of 0.59.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, sell-side analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. JMP Securities raised their target price on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 4th. Guggenheim lifted their price objective on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a report on Monday, March 10th. Oppenheimer increased their target price on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.